Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11023667rdf:typepubmed:Citationlld:pubmed
pubmed-article:11023667lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11023667lifeskim:mentionsumls-concept:C0383327lld:lifeskim
pubmed-article:11023667lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:11023667lifeskim:mentionsumls-concept:C0332152lld:lifeskim
pubmed-article:11023667lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:11023667lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:11023667lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:11023667lifeskim:mentionsumls-concept:C1546857lld:lifeskim
pubmed-article:11023667lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:11023667pubmed:issue10lld:pubmed
pubmed-article:11023667pubmed:dateCreated2000-10-30lld:pubmed
pubmed-article:11023667pubmed:abstractTextInterleukin (IL-)18 is an activator of NK cells and a co-inducer of Th(1)cytokines, sharing structural features with the IL-1 family of proteins. Unlike most other cytokines, IL-18 and IL-1beta lack a signal peptide, have an all beta-pleated sheet structure and are synthesized as biologically inactive precursors (pro-IL-18 and pro-IL-1beta). These precursors are cleaved by caspase-1 (IL-1beta-converting enzyme, ICE) to form the biologically active mature cytokines. Direct expression of mature recombinant human IL-18 in E. coli resulted in a partially active cytokine. We tested the possibility that correct folding of huIL-18 requires its prior synthesis as pro-IL-18. Because caspase-1 is not readily available, we constructed an expression vector encoding human pro-IL-18 in which the caspase-1 cleavage site was mutated into a factor Xa site. To facilitate purification, the mutated pro-IL-18 cDNA was fused in frame to a glutathione-S-transferase (GST) coding sequence. The GST-pro-IL-18 fusion protein was expressed in E. coli, captured on glutathione agarose and mature human IL-18, exhibiting high biological activity was released upon cleavage with factor Xa. This result indicates that correct folding of huIL-18 occurs at the level of pro-IL-18 and provides a practical way to produce biologically active huIL-18.lld:pubmed
pubmed-article:11023667pubmed:languageenglld:pubmed
pubmed-article:11023667pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:citationSubsetIMlld:pubmed
pubmed-article:11023667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11023667pubmed:statusMEDLINElld:pubmed
pubmed-article:11023667pubmed:monthOctlld:pubmed
pubmed-article:11023667pubmed:issn1043-4666lld:pubmed
pubmed-article:11023667pubmed:authorpubmed-author:LinKKlld:pubmed
pubmed-article:11023667pubmed:authorpubmed-author:RubinsteinMMlld:pubmed
pubmed-article:11023667pubmed:authorpubmed-author:MOER ERElld:pubmed
pubmed-article:11023667pubmed:authorpubmed-author:NovickDDlld:pubmed
pubmed-article:11023667pubmed:copyrightInfoCopyright 2000 Academic Press.lld:pubmed
pubmed-article:11023667pubmed:issnTypePrintlld:pubmed
pubmed-article:11023667pubmed:volume12lld:pubmed
pubmed-article:11023667pubmed:ownerNLMlld:pubmed
pubmed-article:11023667pubmed:authorsCompleteYlld:pubmed
pubmed-article:11023667pubmed:pagination1519-25lld:pubmed
pubmed-article:11023667pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:meshHeadingpubmed-meshheading:11023667...lld:pubmed
pubmed-article:11023667pubmed:year2000lld:pubmed
pubmed-article:11023667pubmed:articleTitleProduction of a biologically active human interleukin 18 requires its prior synthesis as PRO-IL-18.lld:pubmed
pubmed-article:11023667pubmed:affiliationDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, 76100, Israel.lld:pubmed
pubmed-article:11023667pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11023667pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11023667lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11023667lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11023667lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11023667lld:pubmed